- Home
- PHUN vs MDXH Comparison
PHUN vs MDXH Comparison
Compare PHUN & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- MDXH
- Stock Information
- Founded
- PHUN 2009
- MDXH 2003
- Country
- PHUN United States
- MDXH Belgium
- Employees
- PHUN N/A
- MDXH N/A
- Industry
- PHUN EDP Services
- MDXH
- Sector
- PHUN Technology
- MDXH
- Exchange
- PHUN Nasdaq
- MDXH Nasdaq
- Market Cap
- PHUN 62.1M
- MDXH 93.1M
- IPO Year
- PHUN N/A
- MDXH 2021
- Fundamental
- Price
- PHUN $2.86
- MDXH $1.46
- Analyst Decision
- PHUN Strong Buy
- MDXH Buy
- Analyst Count
- PHUN 3
- MDXH 1
- Target Price
- PHUN $13.00
- MDXH $6.00
- AVG Volume (30 Days)
- PHUN 396.6K
- MDXH 117.7K
- Earning Date
- PHUN 05-08-2025
- MDXH 04-30-2025
- Dividend Yield
- PHUN N/A
- MDXH N/A
- EPS Growth
- PHUN N/A
- MDXH N/A
- EPS
- PHUN N/A
- MDXH N/A
- Revenue
- PHUN $3,537,000.00
- MDXH $90,049,000.00
- Revenue This Year
- PHUN N/A
- MDXH $23.38
- Revenue Next Year
- PHUN $93.33
- MDXH $16.84
- P/E Ratio
- PHUN N/A
- MDXH N/A
- Revenue Growth
- PHUN N/A
- MDXH 28.29
- 52 Week Low
- PHUN $2.70
- MDXH $1.35
- 52 Week High
- PHUN $14.60
- MDXH $3.50
- Technical
- Relative Strength Index (RSI)
- PHUN 33.15
- MDXH 29.27
- Support Level
- PHUN $2.78
- MDXH $1.35
- Resistance Level
- PHUN $3.15
- MDXH $1.65
- Average True Range (ATR)
- PHUN 0.23
- MDXH 0.13
- MACD
- PHUN 0.00
- MDXH -0.03
- Stochastic Oscillator
- PHUN 13.90
- MDXH 16.92
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.